Clinical trial results:
A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin Type-A (Dysport® 125, 250 or 500 Units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overative bladder.

Summary

EudraCT number	2007-002999-34
Trial protocol	GB DE NL BE FR CZ IT ES
Global end of trial date	15 December 2009

Results information

Result version number	v1 (current)
This version publication date	27 May 2016
First version publication date	27 May 2016

Trial information

Trial identification

Sponsor protocol code	Y-79-52120-126

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Ipsen Pharma
Sponsor organisation address	Ipsen Group, 190 Bath Road, Slough, Berkshire, United Kingdom, SL1 3XE
Public contact	Medical Director, Urology, Ipsen Pharma, clinical.trials@ipsen.com
Scientific contact	Medical Director, Urology, Ipsen Pharma, clinical.trials@ipsen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 March 2011
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 December 2009
Global end of trial reached?	Yes
Global end of trial date	15 December 2009
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To assess the effect of treatment with three doses of botulinum toxin type-A (Dysport®) versus placebo on the number of episodes of urgency and frequency of micturition experienced in continent female subjects with idiopathic overactive bladder (iOAB) at Week 12 in comparison to Baseline.

Protection of trial subjects:

This study was conducted in compliance with the IECs, informed consent regulations, the Declaration of Helsinki, International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines [1], and Food and Drug Administration (FDA) regulations [2, 3]. In addition, this study adhered to all local regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 March 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	Spain: 3
Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	Czech Republic: 22
Country: Number of subjects enrolled	France: 13
Country: Number of subjects enrolled	Germany: 22
Worldwide total number of subjects	63
EEA total number of subjects	63

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	50
From 65 to 84 years	13
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were recruited from 22 sites in 7 European countries (France, Germany, Czech Republic, Belgium, Italy, Netherlands, and Spain).

Pre-assignment

Screening details:

Screened subjects were 82 and 19 subjects were screen failures. Randomized subjects were 63. Two subjects have been randomized but not injected by IMP => Pure ITT Population = Safety Population = 61 subjects.

Period 1

Period 1 title	Princeps Phase: Dysport and Placebo
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

Investigators were to break the study blind for a subject only in cases of medical emergency, where treatment was dependent on knowledge of the study drug received. In the event of the study code for a subject being broken, the Investigator was to immediately notify the responsible Medical Representative or the Clinical Safety Committee. If possible, this notification was to take place before the treatment identification was made. Date and reason(s) for unblinding were to be recorded in CRF.

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A: Dysport 125 units

Arm description:

Intradetrusor Injection of Dysport, 125 units in total

Arm type	Experimental
Investigational medicinal product name	Dysport
Investigational medicinal product code	
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Dysport Intradetrusor Injection, 125 units in total

Arm title	Arm B: Dysport 250 units

Arm description:

Intradetrusor Injection of Dysport, 250 units in total

Arm type	Experimental
Investigational medicinal product name	Dysport
Investigational medicinal product code	
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Dysport Intradetrusor Injection, 250 units in total

Arm title	Arm C: Dysport 500 units

Arm description:

Intradetrusor Injection of Dysport, 500 units in total.

Arm type	Experimental
Investigational medicinal product name	Dysport
Investigational medicinal product code	
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Dysport Intradetrusor Injection, 500 units in total

Arm title	Arm D: Placebo

Arm description:

Intradetrusor injection of Placebo, 0 units in total

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Placebo Intradetrusor injection, 0 units in total

Number of subjects in period 1	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units
Started	9	19	18
Completed	8	14	14
Not completed	1	5	4
Consent withdrawn by subject	-	1	-
Adverse event, non-fatal	-	1	-
Non-specific	1	2	1
Lost to follow-up	-	-	1
Protocol deviation	-	1	1
Lack of efficacy	-	-	1

Number of subjects in period 1	Arm D: Placebo
Started	17
Completed	16
Not completed	1
Consent withdrawn by subject	1
Adverse event, non-fatal	-
Non-specific	-
Lost to follow-up	-
Protocol deviation	-
Lack of efficacy	-

Period 2

Period 2 title	Extension Phase: Dysport and Placebo
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

Investigators were to break the study blind for a subject only in cases of medical emergency, where treatment was dependent on knowledge of the study drug received. In the event of the study code for a subject being broken, the Investigator was to immediately notify the responsible Medical Representative or the Clinical Safety Committee. If possible, this notification was to take place before the treatment identification was made. Date and reason(s) for unblinding were to be recorded in CRF.

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A: Dysport 125 units

Arm description:

Intradetrusor Injection of Dysport, 125 units in total.

Arm type	Experimental
Investigational medicinal product name	Dysport
Investigational medicinal product code	
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Dysport Intradetrusor Injection, 125 units in total

Arm title	Arm B: Dysport 250 units

Arm description:

Intradetrusor Injection of Dysport, 250 units in total

Arm type	Experimental
Investigational medicinal product name	Dysport
Investigational medicinal product code	
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Dysport Intradetrusor Injection, 250 units in total

Arm title	Arm C: Dysport 500 units

Arm description:

Intradetrusor Injection of Dysport, 500 units in total.

Arm type	Experimental
Investigational medicinal product name	Dysport
Investigational medicinal product code	
Other name	Botulinum Toxin Type A
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Dysport Intradetrusor Injection, 500 units in total

Arm title	Arm D: Placebo

Arm description:

Intradetrusor injection of Placebo, 0 units in total

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Placebo Intradetrusor injection, 0 units in total

Number of subjects in period 2[1]	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units
Started	6	6	6
Completed	4	2	5
Not completed	2	4	1
Consent withdrawn by subject	-	1	-
Non-specific	2	2	1
Lost to follow-up	-	1	-
Lack of efficacy	-	-	-

Number of subjects in period 2[1]	Arm D: Placebo
Started	5
Completed	2
Not completed	3
Consent withdrawn by subject	-
Non-specific	1
Lost to follow-up	1
Lack of efficacy	1

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: The number of subjects completed in period 1 (Princeps Phase) is not same as the number of subjects started in the period 2 (Extension Phase) as period 2 (Extension phase) was an optional phase. Of the 52 subjects who completed princeps phase, only 23 subjects were enrolled in the extension phase and 13 subjects completed the extension phase

Baseline characteristics

Reporting groups	
Reporting group title	Arm A: Dysport 125 units
Reporting group description: Intradetrusor Injection of Dysport, 125 units in total	
Reporting group title	Arm B: Dysport 250 units
Reporting group description: Intradetrusor Injection of Dysport, 250 units in total	
Reporting group title	Arm C: Dysport 500 units
Reporting group description: Intradetrusor Injection of Dysport, 500 units in total.	
Reporting group title	Arm D: Placebo
Reporting group description: Intradetrusor injection of Placebo, 0 units in total	

Reporting group values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units
Number of subjects	9	19	18
Age categorical Units: Subjects			

Age continuous			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: years			
arithmetic mean	56.4	54.1	56.9
standard deviation	± 11.27	± 14.15	± 10.34
Gender categorical Units: Subjects			
Female	9	19	18

Height			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: CM			
arithmetic mean	163.4	164.4	163.5
standard deviation	± 6.45	± 6.91	± 6.53
Number of Episodes of Urgency			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Number of Episodes			
arithmetic mean	35.8	34.9	29.8
standard deviation	± 18.7	± 18.9	± 20.8
Number of Episodes of Micturitions			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Number of Episodes			
arithmetic mean	40.6	44.2	41.1
standard deviation	± 11.3	± 12.5	± 14
Number of Episodes of Nocturia			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Number of Episodes			
arithmetic mean	9.3	9.9	6.4

standard deviation	± 3.7	± 5.7	± 5.2
Severity of urgency using Overactive Bladder Questionnaire short form (OAB-Q SF)			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Unit on a scale			
arithmetic mean	35.7	42.5	38.8
standard deviation	± 9.9	± 11.8	± 10
Urine flow rate			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL/sec			
arithmetic mean	19.1	20.3	19.6
standard deviation	± 10.5	± 17.5	± 7.8
Post-micturition residual volume (PMRV) assessed by ultrasound			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL			
arithmetic mean	15.7	13.5	15.5
standard deviation	± 31.9	± 26.6	± 18.5
Maximum Flow Rate			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL/sec			
arithmetic mean	19.1	20.3	19.6
standard deviation	± 10.54	± 17.53	± 7.82
Volume at First Desire to Void			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL			
arithmetic mean	81.6	85.9	114.1
standard deviation	± 48.7	± 60.24	± 63.28
Volume at Urgency			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL			
arithmetic mean	181	149.8	199.5
standard deviation	± 83.12	± 93.94	± 79.76
Maximum Cystometric Capacity (MCC)			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL			
arithmetic mean	240.3	182.7	242.5
standard deviation	± 106.9	± 144	± 88.49
Maximum Detrusor Pressure during Filling			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: cm H2O			
arithmetic mean	39.6	35.9	33.6
standard deviation	± 26.08	± 23.16	± 30.22
Detrusor Pressure at Maximum Flow Rate			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: cm H2O			
arithmetic mean	42.4	39.6	41.2
standard deviation	± 32.41	± 28.2	± 29.75

Bladder Compliance			
Dysport 125 units: N=4, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=14			
Units: mL/cm H2O			
arithmetic mean	33.8	26.5	57.5
standard deviation	± 37.38	± 42.77	± 54.73
Quality of Life (QoL) using EQ-5D: Mobility			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16 EuroQol-5D (EQ-5D)			
Units: Units on a scale			
arithmetic mean	1	1.2	1.3
standard deviation	± 0	± 0.4	± 0.5
QoL using EQ-5D: Self-care			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=13, Placebo: N=16			
Units: Units on a scale			
arithmetic mean	1	1.1	1.1
standard deviation	± 0	± 0.3	± 0.3
QoL using EQ-5D: Usual activities			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Units on a scale			
arithmetic mean	1	1.3	1.1
standard deviation	± 0	± 0.4	± 0.3
QoL using EQ-5D: Pain/Discomfort			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Units on a scale			
arithmetic mean	1.3	1.4	1.4
standard deviation	± 0.5	± 0.5	± 0.5
QoL using EQ-5D: Anxiety/Depression			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Units on a scale			
arithmetic mean	1.1	1.4	1.3
standard deviation	± 0.4	± 0.6	± 0.5

Reporting group values	Arm D: Placebo	Total	
Number of subjects	17	63	
Age categorical Units: Subjects			
Age continuous			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: years			
arithmetic mean	49.1		
standard deviation	± 16.2	-	
Gender categorical Units: Subjects			
Female	17	63	
Height			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: CM			
arithmetic mean	162.4		

standard deviation	± 5.98	-	
Number of Episodes of Urgency			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Number of Episodes			
arithmetic mean	28.7		
standard deviation	± 16.7	-	
Number of Episodes of Micturitions			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Number of Episodes			
arithmetic mean	41.1		
standard deviation	± 11.2	-	
Number of Episodes of Nocturia			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Number of Episodes			
arithmetic mean	10		
standard deviation	± 6.2	-	
Severity of urgency using Overactive Bladder Questionnaire short form (OAB-Q SF)			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Unit on a scale			
arithmetic mean	44.4		
standard deviation	± 13.5	-	
Urine flow rate			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL/sec			
arithmetic mean	22.1		
standard deviation	± 24.2	-	
Post-micturition residual volume (PMRV) assessed by ultrasound			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL			
arithmetic mean	14.3		
standard deviation	± 23.5	-	
Maximum Flow Rate			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL/sec			
arithmetic mean	22.1		
standard deviation	± 24.18	-	
Volume at First Desire to Void			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL			
arithmetic mean	72.5		
standard deviation	± 40.2	-	
Volume at Urgency			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: mL			
arithmetic mean	151		
standard deviation	± 60.36	-	
Maximum Cystometric Capacity (MCC)			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			

Units: mL			
arithmetic mean	241.9		
standard deviation	± 96.29	-	
Maximum Detrusor Pressure during Filling			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: cm H2O			
arithmetic mean	35.8		
standard deviation	± 26.07	-	
Detrusor Pressure at Maximum Flow Rate			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: cm H2O			
arithmetic mean	34.2		
standard deviation	± 20.26	-	
Bladder Compliance			
Dysport 125 units: N=4, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=14			
Units: mL/cm H2O			
arithmetic mean	37.2		
standard deviation	± 28.5	-	
Quality of Life (QoL) using EQ-5D: Mobility			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16 EuroQol-5D (EQ-5D)			
Units: Units on a scale			
arithmetic mean	1.2		
standard deviation	± 0.4	-	
QoL using EQ-5D: Self-care			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=13, Placebo: N=16			
Units: Units on a scale			
arithmetic mean	1		
standard deviation	± 0	-	
QoL using EQ-5D: Usual activities			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Units on a scale			
arithmetic mean	1.1		
standard deviation	± 0.3	-	
QoL using EQ-5D: Pain/Discomfort			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Units on a scale			
arithmetic mean	1.5		
standard deviation	± 0.6	-	
QoL using EQ-5D: Anxiety/Depression			
Dysport 125 units: N=7, Dysport 250 units: N=16, Dysport 500 units: N=14, Placebo: N=16			
Units: Units on a scale			
arithmetic mean	1.5		
standard deviation	± 0.5	-	

End points

End points reporting groups

Reporting group title	Arm A: Dysport 125 units
Reporting group description: Intradetrusor Injection of Dysport, 125 units in total	
Reporting group title	Arm B: Dysport 250 units
Reporting group description: Intradetrusor Injection of Dysport, 250 units in total	
Reporting group title	Arm C: Dysport 500 units
Reporting group description: Intradetrusor Injection of Dysport, 500 units in total.	
Reporting group title	Arm D: Placebo
Reporting group description: Intradetrusor injection of Placebo, 0 units in total	
Reporting group title	Arm A: Dysport 125 units
Reporting group description: Intradetrusor Injection of Dysport, 125 units in total.	
Reporting group title	Arm B: Dysport 250 units
Reporting group description: Intradetrusor Injection of Dysport, 250 units in total	
Reporting group title	Arm C: Dysport 500 units
Reporting group description: Intradetrusor Injection of Dysport, 500 units in total.	
Reporting group title	Arm D: Placebo
Reporting group description: Intradetrusor injection of Placebo, 0 units in total	

Primary: Mean change from baseline in number of episodes of Urgency (Princeps phase)

End point title	Mean change from baseline in number of episodes of Urgency (Princeps phase)
End point description: Intention-to-Treat (ITT) population	
End point type	Primary
End point timeframe: From Day 1 (baseline) to Visit 5 (week 12)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	16	14	16
Units: Number of Episodes				
arithmetic mean (standard deviation)	-24.5 (± 17.2)	-12.8 (± 13.5)	-16.7 (± 21.4)	-13.5 (± 15.2)

Statistical analyses

Statistical analysis title	Q1: Dysport 125 units vs Placebo
Comparison groups	Arm D: Placebo v Arm A: Dysport 125 units
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7426
Method	ANCOVA

Statistical analysis title	Q1: Dysport 250 units vs Placebo
Comparison groups	Arm D: Placebo v Arm B: Dysport 250 units
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9007
Method	ANCOVA

Statistical analysis title	Q1: Dysport 500 units vs Placebo
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.009
Method	ANCOVA

Statistical analysis title	Median: Dysport 125 units vs Placebo
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6741
Method	ANCOVA

Statistical analysis title	Median: Dysport 250 units vs Placebo

Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8347
Method	ANCOVA

Statistical analysis title	Median: Dysport 500 units vs Placebo
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3684
Method	ANCOVA

Statistical analysis title	Q3: Dysport 125 units vs Placebo
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4339
Method	ANCOVA

Statistical analysis title	Q3: Dysport 250 units vs Placebo
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7455
Method	ANCOVA

Statistical analysis title	Q3: Dysport 500 units vs Placebo
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.831
Method	ANCOVA

Primary: Mean change from baseline in number of Episodes of Micturitions (Princeps phase)	
End point title	Mean change from baseline in number of Episodes of Micturitions (Princeps phase)
End point description: ITT population	
End point type	Primary
End point timeframe: From Day 1 (baseline) to Visit 5 (week 12)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	14	14	16
Units: Number of Episodes				
arithmetic mean (standard deviation)	-18.9 (± 7.6)	-10 (± 10.2)	-14.3 (± 12.5)	-10.7 (± 10.3)

Statistical analyses

Statistical analysis title	Dysport 125 units vs Placebo
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0319
Method	ANCOVA

Statistical analysis title	Dysport 250 units vs Placebo
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.604
Method	ANCOVA

Statistical analysis title	Dysport 500 units vs Placebo
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo

Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.257
Method	ANCOVA

Secondary: Mean change from baseline in number of episodes of urgency and frequency of micturition (Princeps phase)

End point title	Mean change from baseline in number of episodes of urgency and frequency of micturition (Princeps phase)
End point description: ITT population	
End point type	Secondary
End point timeframe: Baseline (day 1) to Week 6 (Visit 4)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	15	13	15
Units: Number of Episodes				
arithmetic mean (standard deviation)				
Episodes of Urgency	-22 (± 18.2)	-14 (± 10.1)	-15.4 (± 17.1)	-11 (± 9)
Frequency of Micturition	-14.4 (± 7.9)	-8.2 (± 16.3)	-10.9 (± 10.3)	-10.7 (± 7.5)

Statistical analyses

Statistical analysis title	Q1-Urgency: Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2765
Method	ANCOVA

Statistical analysis title	Q1-Urgency: Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo

Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3282
Method	ANCOVA

Statistical analysis title	Q1-Urgency: Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1463
Method	ANCOVA

Statistical analysis title	Median-Urgency: Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7059
Method	ANCOVA

Statistical analysis title	Median-Urgency: Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4906
Method	ANCOVA

Statistical analysis title	Median-Urgency: Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9228
Method	ANCOVA

Statistical analysis title	Q3-Urgency: Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2353
Method	ANCOVA

Statistical analysis title	Q3-Urgency: Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7289
Method	ANCOVA

Statistical analysis title	Q3-Urgency: Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5278
Method	ANCOVA

Statistical analysis title	Micturition: Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4551
Method	ANCOVA

Statistical analysis title	Micturition: Placebo vs Dysport 250 units
Comparison groups	Arm D: Placebo v Arm B: Dysport 250 units
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3873
Method	ANCOVA

Statistical analysis title	Micturition: Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9517
Method	ANCOVA

Secondary: Mean change from baseline in Frequency of Nocturia (Princeps Phase)	
End point title	Mean change from baseline in Frequency of Nocturia (Princeps Phase)
End point description: ITT population	
End point type	Secondary
End point timeframe: Baseline (Day 1) to Week 6 (visit 4) and Week 12 (visit 5)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	15[1]	13[2]	15[3]
Units: Number of Episodes				
arithmetic mean (standard deviation)				
Baseline to Week 6	-4.6 (± 3.6)	-3.2 (± 5.8)	-1.2 (± 3.4)	-5.5 (± 3.9)
Baseline to Week 12	-5.3 (± 4.3)	-3.4 (± 6.7)	-2.4 (± 4.7)	-4.9 (± 4.7)

Notes:

[1] - Week 12: N=14

[2] - Week 12: N=14

[3] - Week 12: N=16

Statistical analyses

Statistical analysis title	Nocturia: Placebo vs Dysport 125 units (Week 6)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4645
Method	ANCOVA

Statistical analysis title	Nocturia: Placebo vs Dysport 250 units (Week 6)

Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1253
Method	ANCOVA

Statistical analysis title	Nocturia: Placebo vs Dysport 500 units (Week 6)
Comparison groups	Arm D: Placebo v Arm C: Dysport 500 units
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0351
Method	ANCOVA

Statistical analysis title	Nocturia: Placebo vs Dysport 125 units (Week 12)
Statistical analysis description: Number of subjects included in analysis=23	
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8193
Method	ANCOVA

Statistical analysis title	Nocturia: Placebo vs Dysport 250 units (Week 12)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5102
Method	ANCOVA

Statistical analysis title	Nocturia: Placebo vs Dysport 500 units (Week 12)
Statistical analysis description: Number of subjects included in analysis=30	
Comparison groups	Arm D: Placebo v Arm C: Dysport 500 units

Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6737
Method	ANCOVA

Secondary: Mean Change from baseline in severity of urgency using OAB-Q SF

End point title	Mean Change from baseline in severity of urgency using OAB-Q SF

End point description:

ITT population.

The Overactive Bladder Questionnaire-Short Form (OAB-q SF) is a brief, self-administered patient-reported outcomes tool with two scales assessing symptom bother and health-related quality of life (HR-QOL) in patients with OAB.

OAB-q SF consists of a 6-item symptom-bother scale & a 13-item HRQOL scale. HRQOL scale is divided into 3 subscales: Coping (5 items), Sleep (3 items), and Emotional social (5 items). Items are transformed and summarized into 2 domain scores: Symptom Severity and Total HRQOL. Symptom Severity score (average of items 1 through 6) ranged from 0 to 100, with higher scores reflecting greater symptom severity or bother. Total HRQOL score (average of items 1 through 13) ranged from 0 to 100, with higher scores reflecting better HRQOL.

End point type	Secondary

End point timeframe:

Baseline (Day 1) to Week 6 (visit 4), Week 12 (visit 5), Month 6 (Visit 6) and Month 9 (Visit 7)

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	16	14	16
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Baseline to Week 6 (n=7, 16, 14, 16)	-10.5 (± 9.3)	-11.2 (± 12.1)	-17.1 (± 14.1)	-9 (± 19.4)
Baseline to Week 12 (n=6, 15, 14, 16)	-17.8 (± 12.2)	-12.4 (± 14.4)	-15 (± 16)	-8 (± 25.8)
Baseline to Month 6 (n=6, 3, 6, 4)	-17.8 (± 13.8)	-22.2 (± 10.2)	-23.9 (± 8.3)	-20.8 (± 19.1)
Baseline to Month 9 (n=4, 5, 6, 3)	-26.7 (± 8.6)	-18 (± 8.4)	-17.8 (± 9.3)	-16.7 (± 17.6)

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change from baseline in urine flow rate

End point title	Mean Change from baseline in urine flow rate

End point description:

ITT population.

End point type	Secondary

End point timeframe:
Baseline (Day 1) to Week 2 (visit 3) and Week 6 (visit 4)

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	14[4]	13[5]	16
Units: mL/sec				
arithmetic mean (standard deviation)				
Baseline to Week 2	2.3 (± 5.3)	-0.2 (± 12)	-2.2 (± 11.4)	-4.2 (± 26.9)
Baseline to Week 6	-4 (± 6.5)	0.5 (± 22.4)	0.6 (± 21.1)	1.3 (± 29.5)

Notes:
[4] - Week 6: N=15
[5] - Week 6: N=14

Statistical analyses

Statistical analysis title	Q1: Placebo vs Dysport 125 units (Week 2)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4212
Method	ANCOVA

Statistical analysis title	Q1: Placebo vs Dysport 250 units (Week 2)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6019
Method	ANCOVA

Statistical analysis title	Q1: Placebo vs Dysport 500 units (Week 2)
Comparison groups	Arm D: Placebo v Arm C: Dysport 500 units
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1861
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 125 units (Week 2)

Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6296
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 250 units (Week 2)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6741
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 500 units (Week 2)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6413
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 125 units (Week 2)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1122
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 250 units (Week 2)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8201
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 500 units (Week 2)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5478
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 125 units (Week 6)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2587
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units (Week 6)
Statistical analysis description: Number of subjects included in analysis=31	
Comparison groups	Arm D: Placebo v Arm B: Dysport 250 units
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.759
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units (Week 6)
Statistical analysis description: Number of subjects included in analysis=30	
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5971
Method	ANCOVA

Secondary: Mean Change from baseline in PMRV assessed by ultrasound Assessment	
End point title	Mean Change from baseline in PMRV assessed by ultrasound Assessment
End point description: ITT population.	

End point type	Secondary

End point timeframe:

Baseline (Day 1) to Week 2 (Visit 3) and Week 6 (Visit 4)

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	16[6]	14	16
Units: mL				
arithmetic mean (standard deviation)				
Baseline to Week 2	5.9 (± 40.3)	37.8 (± 80.5)	30 (± 56.8)	18.4 (± 47.8)
Baseline to Week 6	-4.9 (± 18.2)	31.5 (± 77.7)	44.5 (± 75.2)	26.1 (± 64.2)

Notes:

[6] - Week 6: N=15

Statistical analyses

Statistical analysis title	Q1: Placebo vs Dysport 125 units (Week 2)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6042
Method	ANCOVA

Statistical analysis title	Q1: Placebo vs Dysport 250 units (Week 2)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.073
Method	ANCOVA

Statistical analysis title	Q1: Placebo vs Dysport 500 units (Week 2)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9536
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 125 units (Week 2)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6042
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 250 units (Week 2)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.073
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 500 units (Week 2)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9536
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 125 units (Week 2)
Comparison groups	Arm D: Placebo v Arm A: Dysport 125 units
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5968
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 250 units (Week 2)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo

Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0098
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 500 units (Week 2)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3338
Method	ANCOVA

Statistical analysis title	Q1: Placebo vs Dysport 125 units (Week 6)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1379
Method	ANCOVA

Statistical analysis title	Q1: Placebo vs Dysport 250 units (Week 6)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0265
Method	ANCOVA

Statistical analysis title	Q1: Placebo vs Dysport 500 units (Week 6)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1464
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 125 units (Week 6)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1379
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 250 units (Week 6)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0265
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 500 units (Week 6)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1464
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 125 units (Week 6)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2735
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 250 units (Week 6)
Statistical analysis description: Number of subjects included in analysis = 31	
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo

Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1578
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 500 units (Week 6)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.43
Method	ANCOVA

Secondary: Urodynamic Parameters: Mean Change from baseline in Maximum Flow Rate

End point title	Urodynamic Parameters: Mean Change from baseline in Maximum Flow Rate
End point description: ITT population	
End point type	Secondary
End point timeframe: Baseline (Day 1) to Week 12 (Visit 5)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	12	13	15
Units: mL/sec				
arithmetic mean (standard deviation)	-0.9 (± 9.06)	25.6 (± 79.07)	1.1 (± 10.78)	2.5 (± 8.81)

Statistical analyses

Statistical analysis title	Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9808
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1542
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8905
Method	ANCOVA

Secondary: Urodynamic Parameters: Mean Change from baseline in PMRV	
End point title	Urodynamic Parameters: Mean Change from baseline in PMRV
End point description: ITT population	
End point type	Secondary
End point timeframe: Baseline(Day 1) to Week 12 (Visit 5)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	13	13	15
Units: mL				
arithmetic mean (standard deviation)	-2 (± 41.19)	59.6 (± 91.86)	50.5 (± 67.29)	-1.6 (± 35.01)

Statistical analyses

Statistical analysis title	Q1: Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo

Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8791
Method	ANCOVA

Statistical analysis title	Q1: Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5791
Method	ANCOVA

Statistical analysis title	Q1: Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1101
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8791
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5791
Method	ANCOVA

Statistical analysis title	Median: Placebo vs Dysport 500 units
Comparison groups	Arm D: Placebo v Arm C: Dysport 500 units
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1101
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9631
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Q3: Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0109
Method	ANCOVA

Secondary: Urodynamic Parameters: Mean change from baseline in Volume at First Desire to Void

End point title	Urodynamic Parameters: Mean change from baseline in Volume at First Desire to Void
End point description: ITT population	
End point type	Secondary
End point timeframe: Baseline (Day 1) to Week 12 (visit 5)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	11	13	14
Units: mL				
arithmetic mean (standard deviation)	23.1 (± 21.63)	49.7 (± 79.89)	40.9 (± 74.42)	17.1 (± 54.27)

Statistical analyses

Statistical analysis title	Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6565
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	25
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1284
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0153
Method	ANCOVA

Secondary: Urodynamic Parameters: Mean change from Baseline in Volume at Urgency

End point title	Urodynamic Parameters: Mean change from Baseline in Volume at Urgency

End point description: ITT population	
End point type	Secondary
End point timeframe: Baseline (Day 1) to Week 12 (Visit 5)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	12	13	14
Units: mL				
arithmetic mean (standard deviation)	25.4 (± 80.11)	48.5 (± 119.17)	112.2 (± 128.93)	21.6 (± 90.85)

Statistical analyses

Statistical analysis title	Placebo vs Dysport 125 units
Comparison groups	Arm D: Placebo v Arm A: Dysport 125 units
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7295
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	26
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8225
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0055
Method	ANCOVA

Secondary: Urodynamic Parameters: Mean Change from baseline in MCC	
End point title	Urodynamic Parameters: Mean Change from baseline in MCC
End point description: ITT population	
End point type	Secondary
End point timeframe: Baseline (Day 1) to Week 12 (Visit 5)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	12	13	14
Units: mL				
arithmetic mean (standard deviation)	-26.6 (± 79.31)	53.6 (± 92.14)	101.8 (± 96.19)	-19 (± 79.32)

Statistical analyses

Statistical analysis title	Placebo vs Dysport 125 units
Comparison groups	Arm D: Placebo v Arm A: Dysport 125 units
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8341
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	26
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2712
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo

Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Secondary: Urodynamic Parameters: Mean change from baseline in Maximum Detrusor Pressure during Filling (Pdetmax)

End point title	Urodynamic Parameters: Mean change from baseline in Maximum Detrusor Pressure during Filling (Pdetmax)
End point description: ITT population.	
End point type	Secondary
End point timeframe: Baseline (Day 1) to Week 12 (Visit 5)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	12	13	14
Units: cm H2O				
arithmetic mean (standard deviation)	-6.3 (± 16.55)	-7.4 (± 30.62)	-9.5 (± 25.57)	-12.2 (± 27.6)

Statistical analyses

Statistical analysis title	Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4844
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	26
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5393
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8337
Method	ANCOVA

Secondary: Urodynamic Parameters: Mean change from baseline in Detrusor Pressure at Maximum Flow Rate

End point title	Urodynamic Parameters: Mean change from baseline in Detrusor Pressure at Maximum Flow Rate
End point description: ITT population	
End point type	Secondary
End point timeframe: Baseline (Day 1) to Week 12 (Visit 5)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	11	13	14
Units: cm H2O				
arithmetic mean (standard deviation)	-4 (± 16.05)	-13 (± 34.81)	1.4 (± 26.61)	0.9 (± 16.99)

Statistical analyses

Statistical analysis title	Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9703
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo

Number of subjects included in analysis	25
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8713
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6378
Method	ANCOVA

Secondary: Urodynamic Parameters: Mean change from baseline in Bladder Compliance

End point title	Urodynamic Parameters: Mean change from baseline in Bladder Compliance
End point description: ITT population	
End point type	Secondary
End point timeframe: Baseline (Day 1) to Week 12 (Visit 5)	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	11	12	11
Units: mL/cm H2O				
arithmetic mean (standard deviation)	21 (± 12.57)	27.3 (± 54.77)	33.3 (± 129.45)	0.7 (± 19.78)

Statistical analyses

Statistical analysis title	Placebo vs Dysport 125 units
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo

Number of subjects included in analysis	15
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6866
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.511
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2322
Method	ANCOVA

Secondary: Mean change from baseline in QoL using EQ-5D

End point title	Mean change from baseline in QoL using EQ-5D

End point description:

ITT population

EuroQol-5D (EQ-5D): Self-reported health outcome measure, consisting of Part I: Descriptive system & Part II: Visual Analogue Scale (VAS).

Part I has 5 single-item dimensions: Mobility, Self-care, Usual activities, Pain/Discomfort, & Anxiety/Depression. Each dimension has a 5 point response scale indicating problem level, where 5=Best health & 25=Worst health.

Part II uses a vertical graduated VAS (thermometer), ranging from 0 (Worst health) to 100 (Best health).

End point type	Secondary

End point timeframe:

Baseline (Day 1) to Week 6 (Visit 4) and Week 12 (Visit 5)

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7[7]	16[8]	14[9]	16
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Mobility (Week 6)	0 (± 0)	0 (± 0.4)	-0.1 (± 0.3)	-0.1 (± 0.3)
Self-care (Week 6)	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Usual Activities (Week 6)	0 (± 0)	0 (± 0)	0.1 (± 0.4)	0 (± 0)
Pain/Discomfort (Week 6)	-0.3 (± 0.5)	0.1 (± 0.3)	-0.2 (± 0.4)	-0.3 (± 0.7)
Anxious/Depressed (Week 6)	0 (± 0)	0 (± 0.4)	0 (± 0.4)	-0.1 (± 0.5)
Mobility (Week 12)	0 (± 0)	0 (± 0.4)	-0.1 (± 0.4)	0 (± 0)
Self-care (Week 12)	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Usual Activities (Week 12)	0 (± 0)	0.1 (± 0.3)	0.1 (± 0.3)	0.1 (± 0.4)
Pain/Discomfort (Week 12)	-0.3 (± 0.5)	0.1 (± 0.5)	0.1 (± 0.7)	-0.2 (± 0.7)
Anxious/Depressed (Week 12)	0 (± 0)	-0.1 (± 0.5)	0.1 (± 0.5)	-0.1 (± 0.6)

Notes:

[7] - Week 12 (Visit 5): N=6

[8] - Week 12 (Visit 5): N=15.

Anxious/Depressed Week 12: N=14.
[9] - Pain/Discomfort Week 6: N=13

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects who are normalised

End point title	Number of subjects who are normalised

End point description:

ITT population

Normalised defined as micturitions <8 per 24 h

End point type	Secondary

End point timeframe:

Week 6 and Week 12

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	16	14	16
Units: Number of subjects				
Week 6	4	3	5	5
Week 12	6	2	4	4

Statistical analyses

Statistical analysis title	Normalized: Placebo vs Dysport 125 units (Week 6)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2967
Method	Regression, Logistic

Statistical analysis title	Normalized: Placebo vs Dysport 250 units (Week 6)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4129
Method	Regression, Logistic

Statistical analysis title	Normalized: Placebo vs Dysport 500 units (Week 6)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7777
Method	Regression, Logistic

Statistical analysis title	Normalized: Placebo vs Dysport 125 units (Week 12)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0183
Method	Regression, Logistic

Statistical analysis title	Normalized: Placebo vs Dysport 250 units (Week 12)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4691
Method	Regression, Logistic

Statistical analysis title	Normalized: Placebo vs Dysport 500 units (Week 12)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8254
Method	Regression, Logistic

Secondary: Number of subjects who Reported No Incidence of Urgencies	
End point title	Number of subjects who Reported No Incidence of Urgencies
End point description: ITT population.	
End point type	Secondary
End point timeframe: At Week 6 and Week 12	

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	16	14	16
Units: Number of subjects				
Week 6	0	0	0	0
Week 12	0	3	1	1

Statistical analyses

Statistical analysis title	Placebo vs Dysport 125 units (Week 12)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9709
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units (Week 12)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo

Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2182
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units (Week 12)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9297
Method	ANCOVA

Secondary: Number of subjects who are Responders with Respect to Both Urgency and Micturitions

End point title	Number of subjects who are Responders with Respect to Both Urgency and Micturitions

End point description:

ITT population

Responders defined as decrease of at least 25% of the number of urgency and micturition episodes from Baseline

Positive response is defined as >= 25% reduction compared to baseline in both urgency and micturitions

End point type	Secondary

End point timeframe:

At week 6 and week 12

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	16	14	16
Units: Number of subjects				
Week 6	5	7	6	5
Week 12	6	6	8	7

Statistical analyses

Statistical analysis title	Placebo vs Dysport 125 units (Week 6)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo

Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1075
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units (Week 6)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4577
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units (Week 6)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.49
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 125 units (Week 12)
Comparison groups	Arm A: Dysport 125 units v Arm D: Placebo
Number of subjects included in analysis	23
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0865
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 250 units (Week 12)
Comparison groups	Arm B: Dysport 250 units v Arm D: Placebo
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9607
Method	ANCOVA

Statistical analysis title	Placebo vs Dysport 500 units (Week 12)
Comparison groups	Arm C: Dysport 500 units v Arm D: Placebo
Number of subjects included in analysis	30
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4656
Method	ANCOVA

Secondary: Safety: Number of subjects reporting adverse events (AEs) - Princeps and Extension phases

End point title	Safety: Number of subjects reporting adverse events (AEs) - Princeps and Extension phases

End point description:

Safety population.

Treatment Emergent Adverse Event (TEAE)
Serious Adverse Events (SAEs)

End point type	Secondary

End point timeframe:

Up to Month 9 (Visit 7E)

End point values	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units	Arm D: Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	17	18	17
Units: Number of subjects				
Adverse Events	2	7	7	5
TEAEs	2	7	7	4
Mild (TEAEs)	0	0	5	3
Moderate (TEAEs)	1	5	2	1
Severe (TEAEs)	1	2	0	0
Related (TEAEs)	1	4	3	2
Not Related (TEAEs)	1	3	4	2
TEAEs Leading to Drug Withdrawal	0	0	0	0
TEAEs Leading to Death	0	0	0	0
SAEs	1	1	0	0

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
Up to Month 9 (Visit 7E)	
Adverse event reporting additional description:	
Safety population	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	11.0

Reporting groups	
Reporting group title	Arm A: Dysport 125 units
Reporting group description:	
Dysport 125 units single injection	
Reporting group title	Arm B: Dysport 250 units
Reporting group description:	
Dysport 250 units single injection	
Reporting group title	Arm C: Dysport 500 units
Reporting group description:	
Dysport 500 units single injection	
Reporting group title	Arm D: Placebo
Reporting group description:	
Placebo 0 units single injection	

Serious adverse events	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 9 (11.11%)	1 / 17 (5.88%)	0 / 18 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder cancer			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 17 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 17 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Arm D: Placebo		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 17 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder cancer			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Arm A: Dysport 125 units	Arm B: Dysport 250 units	Arm C: Dysport 500 units
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 9 (22.22%)	7 / 17 (41.18%)	7 / 18 (38.89%)
Investigations			

Residual urine volume increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Headache			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Injection site pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Defaecation urgency			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Abdominal discomfort			
subjects affected / exposed	1 / 9 (11.11%)	0 / 17 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Abdominal distension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Asthma			

subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Cough			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Micturition urgency			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Urethral pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Urinary incontinence			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	1 / 18 (5.56%)
occurrences (all)	0	2	1
Bladder pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Dysuria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Urethral stenosis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Urge incontinence			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 9 (0.00%)	1 / 17 (5.88%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Endocrine disorders			

Hypothyroidism			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 17 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Tendonitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Infections and infestations			
Viral infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Upper respiratory tract infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 17 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Urinary tract infection			
subjects affected / exposed	1 / 9 (11.11%)	2 / 17 (11.76%)	1 / 18 (5.56%)
occurrences (all)	1	3	1

Non-serious adverse events	Arm D: Placebo		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 17 (23.53%)		
Investigations			
Residual urine volume increased			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Injection site pain			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Defaecation urgency			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Abdominal discomfort			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Abdominal distension			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences (all)	1		
Abdominal pain			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Micturition urgency			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Urethral pain			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		

Urinary incontinence subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2		
Bladder pain subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0		
Dysuria subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Urethral stenosis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0		
Urge incontinence subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1		
Urinary retention subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0		
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0		
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0		
Tendonitis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0		
Infections and infestations Viral infection			

subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		
Urinary tract infection			
subjects affected / exposed	0 / 17 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 January 2008	Addition of following exclusion criterion: - The subject has any relevant neurological conditions or history of dysphagia or history of aspiration pneumonia.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to insufficient subject enrolment, the study was stopped prematurely.

Notes: